Global Oligonucleotide Therapeutics Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.

Market Analysis and Insights: Global Oligonucleotide Therapeutics Market
The research report studies the Oligonucleotide Therapeutics market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Oligonucleotide Therapeutics market size is projected to reach US$ 7961.1 million by 2026, from US$ 3151.7 million in 2020, at a CAGR of 16.7% during 2021-2026.

Global Oligonucleotide Therapeutics Scope and Segment
The global Oligonucleotide Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Oligonucleotide Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.

Segment by Type, the Oligonucleotide Therapeutics market is segmented into
Antisense Oligonucleotide
Aptamer
Other
In 2018, antisense oligonucleotides accounted for the highest proportion of income, reaching 96.52%.

Segment by Application, the Oligonucleotide Therapeutics market is segmented into
Neuromuscular Diseases
ATTR
Hepatic VOD
Other
According to the application, neuromuscular diseases and hepatic VOD are the most important, accounting for 51.69% and 42.23%, respectively.

Global Oligonucleotide Therapeutics market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa

The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.

The major vendors covered:
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics